Monte Rosa Therapeutics (GLUE) Share-based Compensation Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -40.86% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | 832.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 832.43% |
| Dec 31, 2025 | -3.58% |
| Sep 30, 2025 | 1.91% |
| Jun 30, 2025 | 8.71% |
| Mar 31, 2025 | 8.72% |
| Dec 31, 2024 | 9.70% |
| Sep 30, 2024 | -87.06% |
| Jun 30, 2024 | 4,402.00% |
| Mar 31, 2024 | 22.62% |
| Dec 31, 2023 | 22.49% |
| Sep 30, 2023 | 16,450.00% |
| Jun 30, 2023 | -99.72% |
| Mar 31, 2023 | 76.54% |
| Dec 31, 2022 | 79.20% |
| Sep 30, 2022 | -99.23% |
| Jun 30, 2022 | 3,383.81% |
| Mar 31, 2022 | 793.25% |
| Dec 31, 2021 | 823.38% |
| Sep 30, 2021 | 57,900.00% |
| Jun 30, 2021 | 843.52% |